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Hypoxia often occurs under various physiological and pathophysiological conditions, including solid tumors; it is linked to ma-
lignant transformation, metastatic progression, and treatment failure or resistance. Tip110 protein plays important roles in sev-
eral known physiological and pathophysiological processes, including cancers. Thus, in the present study we investigated the
regulation of Tip110 expression under hypoxia. Hypoxia led to Tip110 protein degradation through the ubiquitin-proteasome
system. Under hypoxia, Tip110 stabilized p53, which in return destabilized Tip110. In addition, Tip110 regulated hypoxia-in-
ducible factor 1 (HIF-1), likely through enhancement of its protein stability. Furthermore, Tip110 upregulated p300, a known
coactivator for both p53 and HIF-1. Expression of a p53(22/23) mutant deficient in p300 binding accelerated Tip110 degrada-
tion under hypoxia. Tip110 knockdown resulted in the inhibition of cell proliferation and cell death in the presence of p53. Fi-
nally, significantly less Tip110, p53, and HIF-1was detected in the hypoxic region of bone metastasis tumors in a mouse model
of humanmelanoma cells. Taken together, these results suggest Tip110 is an important mediator in the cross talk between p53
and HIF-1 in response to hypoxic stress.
Hypoxia is the common characteristic of many solid tumors.The adaptation of cells to hypoxia is mediated by hypoxia-
inducible factor (HIF), a transcription factor, at the molecular
level (1). Under normal oxygen conditions (normoxia), HIF-1 is
hydroxylated, which promotes its binding to the ubiquitin ligase
von Hippel-Lindau protein (pVHL), thereby targeting it for ubiq-
uitin-proteasome system (UPS)-mediated degradation. However,
under hypoxic conditions, HIF-1 becomes less hydroxylated,
leading to its rapid accumulation and subsequent activation of
hundreds of genes involved in cell survival, as well as genes in-
volved in apoptosis (2). This opposing function of HIF in deter-
mining different cell fates is dependent on the physiopathological
context and differential binding to other key partners, such as
tumor suppressor protein p53.
Similarly to HIF-1, p53 stability is also regulated by the hy-
poxic condition. p53 plays a crucial role in response to DNA dam-
age, aberrant cell control, apoptosis, and senescence (3, 4). p53
function is constitutively regulated in different types of tumors
under hypoxia by different mechanisms, such as p53 mutation,
expression of inhibitors, or unknown host regulatory elements
leading to induction of resistance to p53-mediated apoptosis. In
normal cells, p53 protein expression is maintained at a low, often
undetectable level due to ubiquitin-mediated proteasome degra-
dation (5). Upon exposure to stress, such as oncogenic activation
and certain hypoxic situations, p53 becomes stabilized. Conse-
quently, p53 activates genes involved in cell cycle regulation and
genes involved in apoptotic events (4).
HIV-1 Tat-interacting protein 110 (Tip110), also known as
“squamous cell carcinoma antigen recognized by T cells 3”
(SART3), is a nuclear protein and contains two RNA recognition
motifs (RRMs) (6, 7). Tip110 regulates transcription of viral and
several host genes and plays an important role in pre-mRNA splic-
ing and spliceosome assembly (7–12). Tip110 expression is essen-
tial for embryonic development (13). Recently we have reported
that UPS-mediated degradation of human Tip110 (hTip110) is
regulated by oncogenic USP15 protein (14). Tip110 protein ex-
pression is very low in the normal tissues and nonproliferating
cells (15) but becomes highly elevated in a number of malignant
tumor cell lines and cancerous tissues as well as stem cells (16–25).
Furthermore, Tip110 serves as a tumor antigen and could be used
as a cancer immunotherapy adjuvant (26–28). The Tip110 protein
expression level is also important for hematopoietic stem cell dif-
ferentiation, which resides in the hypoxic bone marrow environ-
ment through reciprocal regulation of transcription factor c-Myc
expression (19) and alternative splicing of OCT4 (20). In addition,
Tip110 interacts with oncogenic transcription factor YB-1 and
promotes the inclusion of exon 5 in CD44 alternative splicing
(11). Both c-Myc and YB-1 proteins are regulated under hypoxic
conditions (29, 30).
In the present study, we investigated Tip110 regulation under
hypoxia and its relationship to HIF-1 and p53, two important
regulators of hypoxia. We took advantage of a pair of osteosar-
coma cell lines that differ in p53 status as an experimental model.
We showed that Tip110 was degraded under hypoxia in vitro and
in a mouse model of bone metastasis. The degradation was mainly
mediated by the ubiquitin-proteasome system. The regulation of
Tip110 protein level under hypoxia was p53 dependent; Tip110
overexpression enhanced HIF-1 protein stability. These findings
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together suggest an important role of Tip110 in the p53-HIF1
cross talk in a tumor hypoxic environment.
MATERIALS AND METHODS
Cell cultures and transfection. U2OS (p53/), Soas-2 (p53/), and
SW480 cells were purchased from the American Tissue Culture Collection
(ATCC, Manassas, VA) and cultured in Dulbecco’s modified Eagle’s me-
dium containing 10% fetal bovine serum (FBS). The parental 1205Lu
melanoma cell line (31) was grown in a composite medium (W489) con-
sisting of 3 parts MCBD153 (Sigma-Aldrich, St. Louis, MO) and 1 part
L15 (Sigma-Aldrich), supplemented with 4% FBS and 2 mM L-glutamine
(Sigma-Aldrich). The cell lines were supplemented with 100 IU/ml peni-
cillin and 100g/ml streptomycin and cultured at 37°C, 21% O2, and 5%
CO2 in a standard and humidified tissue culture chamber (normoxia). For
hypoxia studies, the cells were cultured at 37°C under hypoxia (1% O2, 5%
CO2, and 99% N2) or severe hypoxia (0.1% O2, 5% CO2, and 99.9% N2) in
a humidified chamber of an INVIVO2 200 hypoxia workstation (Ruskinn
Technologies, Bridgend, United Kingdom). Plasmid DNA and small in-
terfering RNA (siRNA) were transfected using Lipofectamine 2000 ac-
cording to the manufacturer’s instructions (Invitrogen, Carlsbad, CA).
DNA plasmids and siRNAs. The plasmids for expression of hTip110-
His, Tip110 –promoter-driven luciferase reporter gene (Tip110-Prom-
Luc), and p300 promoter-driven luciferase reporter gene (p300-Prom-
Luc) were described elsewhere (9, 10). The plasmid for expression of
hemagglutinin-tagged ubiquitin (Ub-HA) was kindly provided by Mark
Hannink of University of Missouri, Columbia, MO (32). p53 and p53(22/
23) plasmids were kindly provided by Jiayuh Lin of The Research Institute
at Nationwide Children’s Hospital, Columbus, OH (33). Tip110 siRNA
and control siRNA were purchased from Thermo Scientific (Lafayette,
CO). p53 siRNA was purchased from Sigma-Aldrich.
Western blotting. Cells were washed in phosphate-buffered saline
(PBS) and lysed in lysis buffer (50 mM Tris-HCl, pH 8.0, 280 mM NaCl,
0.5% NP-40, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, 2 mM phenyl-
methylsulfonyl fluoride [PMSF], and protease inhibitor cocktail). Lysates
were cleared of cell debris by centrifugation and fractionated by SDS-
PAGE, followed by Western blotting. The antibodies were monoclonal
anti-Tip110 (19), polyclonal anti-HIF-1 (H-206, sc-10790; Santa Cruz
Biotechnologies, Santa Cruz, CA), polyclonal anti-p53 (FL-393, sc-6243;
Santa Cruz Biotechnologies), monoclonal anti-p53 (DO-1, sc-126; Santa
Cruz Biotechnologies), monoclonal anti-p300 (Novus Biological, CO),
monoclonal anti-His tag (G020; ABM, Richmond, British Columbia,
Canada), and monoclonal anti--actin (clone AC-15; Sigma, St. Louis,
MO). ImageJ was used to quantitate protein expression levels.
qRT-PCR. RNA was extracted from cells using TRizol (Invitrogen)
according to the manufacturer’s instructions. RNA (1 g) was converted
into cDNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA)
and used as the template for PCR using Sso Advanced SYBR green Super-
mix and the CFX96 real-time PCR detection system (Bio-Rad). The quan-
titative reverse transcription-PCR (qRT-PCR) primers used and their se-
quences are as follows: for -actin, 5=-AAA CTG GAA CGG TGA AGG
TG-3= and 5=-AGA GAA GTG GGG TGG CTT TT-3=; for Tip110, 5=-
GGC TAG GAT TGA GGC TCG ACT G-3= and 5=-GGG TGT CAC CAT
GAG CTC TTT CC-3=; and for p53, 5=-CTC AGA TAG CGA TGG TCT
GG-3= and 5=-GGT GGT ACA GTC AGA GCC AA-3=. Threshold cycle
(CT) values were calculated using Bio-Rad CFX manager software. The
2CT value was calculated to represent the fold change of the target gene
mRNA under hypoxia compared to that under normoxia and normalized
using -actin as the reference.
Luciferase reporter gene assay.The firefly luciferase activity was mea-
sured using the luciferase assay substrate (Promega, Madison, WI) ac-
cording to the manufacturer’s instructions. Briefly, cells were washed with
ice-cold PBS and lysed with 120 l 1 firefly luciferase lysis buffer (Pro-
mega) at room temperature for 15 min. The lysates were centrifuged at
12,000 g for 2 min to remove cell debris. The cleared lysates (5l) were
then mixed with 20 l firefly luciferase substrate (Promega), and the lu-
ciferase activity was measured using an Opticomp luminometer (MGM
Instruments, Hamden, CT).
Flow cytometry. For cell cycle analysis, 	70% confluent cells were
grown on a 12-well tissue culture plate. On the following day, cells were
transfected with an universal control siRNA (Si-Ctrl) or Tip110 siRNA
(si-Tip110) and cultured for 48 h. Cells were washed with ice-cold PBS,
trypsinized, harvested, and fixed in 1 ml of 70% ethanol and then stored at
20°C until the analysis. Cells were centrifuged at 700 g for 5 min. The
cell pellets were washed two times with PBS and suspended in 500 l
propidium iodide (PI) (Sigma) staining solution (40 g/ml PI in 3.8 mM
sodium citrate) and 50 l RNase A (10 g/ml) (Sigma) and incubated at
37°C for 30 min. Cell cycle was analyzed using FACScaliber (Becton Dick-
inson, CA) and ModFit LT software (Becton Dickinson, CA). A total of
50,000 cells were analyzed.
MTT assay. Cells were seeded in a 12-well tissue culture plate and
cultured overnight. The cells were transfected with the universal control
siRNA (Si-Ctrl) or Tip110 siRNA (si-Tip110) for 48 h and cultured under
normoxia (21% O2) or hypoxia (1% O2) for 24 h. MTT [3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] (120 l of 50 mg/
ml) was added to the culture and incubated for 4 to 5 h. The culture media
were then removed, and the violet crystals in the well were dissolved by
addition of 200 l acid-isopropanol (3:22 ratio mixture of 0.2 N HCl and
isopropanol), followed by gentle shaking at room temperature for 20 min.
Optical densities at 655 and 595 nm (OD655 and OD595, respectively) were
taken using an iMark microplate absorbance reader (Bio-Rad) and used
to calculate the differences.
Data analysis. Where appropriate, values are expressed as means 

standard deviations (SD) from triplicate samples. All comparisons were
made based on the control using a two-tailed Student’s t test. P values of
0.05 were considered statistically significant, 0.01 highly significant,
and 0.001 strongly significant. All data are representative of multiple
independent experiments.
RESULTS
Hypoxia promoted Tip110 protein degradation. Our first at-
tempt was to investigate the status of the Tip110 protein level
under hypoxia. Cells of the colon adenocarcinoma line SW480
were transfected with Tip110-His or its backbone cDNA3. One set
of transfected cells was cultured under hypoxia (1% O2), and the
other set of cells was cultured under normoxia (21% O2). After
being cultured for 24 h, the cells were harvested for Tip110 expres-
sion by Western blotting. Compared to normoxia, hypoxia
showed considerable decreases in both endogenous and exoge-
nous Tip110 proteins (Fig. 1A and B). To determine whether UPS
was involved in hypoxia-induced Tip110 degradation, the trans-
fected cells were treated with MG132, a well-characterized protea-
somal inhibitor of the 26S proteasome within the UPS that detects
and degrades ubiquitinated proteins in the cells, followed by
Tip110 analysis by Western blotting. MG132 treatment led to sta-
bilization of endogenous and exogenous Tip110 protein under
hypoxic conditions (Fig. 1A and B). Previously, we reported that
Tip110 is ubiquitinated (14). Thus, to determine whether hypoxia
would affect Tip110 ubiquitination, cells were transfected with
Tip110-His, Ub-HA, or both. Immunoprecipitation by an anti-
His antibody, followed by Western blotting by an anti-HA anti-
body, detected more ubiquitinated Tip110 under hypoxia than
that under normoxia (Fig. 1C). These results suggest that hypoxia
induced Tip110 protein degradation through the UPS. Similar
results were obtained using human embryonic kidney fibroblasts
of the 293T line (data not shown).
p53 and HIF-1 are two transcription factors that have major
roles in numerous cellular pathways in response to hypoxia (34).
Thus, we next determined whether Tip110 expression would alter
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p53 and HIF1- protein levels. SW480 cells were transfected with
increasing amounts of Tip110-His and monitored for HIF-1 and
p53 expression by Western blotting. Increasing Tip110 expression
resulted in upregulation of both p53 and HIF-1 protein in a dose-
dependent manner (Fig. 2), suggesting possible roles of Tip110 in the
regulation of both p53 and HIF-1under limited-oxygen conditions.
Increased Tip110 degradation by p53 expression under hyp-
oxia. SW480 cells express a mutated p53 (35–37). Because of the
possible roles of Tip110 in the regulation of p53, we decided to use
cell line U2OS, a human bone osteosarcoma line that expresses
wild-type p53, and its cognate p53-null cell line, Saos-2, for the
rest of this study. To determine the effects of different hypoxic
conditions on the endogenous Tip110 protein stability in the con-
text of p53, U2OS and Saos-2 cells were cultured under 21, 1, and
0.1% (severe hypoxia) O2 for 24 h, and the cells were harvested for
Tip110 expression by Western blotting. In U2OS cells, hypoxia led
to lower endogenous Tip110 protein than normoxia, and severe
hypoxia showed even more lower endogenous Tip110 protein
than normoxia (Fig. 3). In Saos-2 cells, there was little change of
endogenous Tip110 protein from normoxia to hypoxia, and
there was only a slight decrease of endogenous Tip110 protein
even under severe hypoxia. Quantitation showed that U2OS
exhibited more rapid endogenous Tip110 degradation than
Saos-2 (Fig. 3B). Meanwhile, the levels of HIF-1, p300, and p53
in those cells were also determined by Western blotting. As ex-
pected, HIF-1 protein was stabilized in both U2OS and Saos-2
under hypoxic and severely hypoxic conditions but with different
kinetics (38). Higher levels of p300 and p53 proteins were also
detected in U2OS under conditions of hypoxia and severe hyp-
oxia. To exclude the possibility that different cellular backgrounds
other than p53 expression affect the Tip110 expression level,
U2OS cells were transfected with control or p53 siRNA, cultured
under 21, 1, and 0.1% O2 for 24 h, and analyzed for p53, Tip110,
and HIF-1 expression by Western blotting. Similarly, hypoxia
led to a significantly lower level of endogenous Tip110 in U2OS
cells but not in USOS cells with p53 knocked down (Fig. 3C and
D). These results together suggest that p53 regulates Tip110 deg-
radation under hypoxic conditions.
Transactivation of Tip110 expression by p53. To further ver-
ify the relationship between p53 and Tip110, Saos-2 cells were
transfected with increasing amounts of p53 expression plasmid,
cultured under normoxia and hypoxia, and harvested for Tip110
expression by Western blotting. p53 expression increased the en-
dogenous Tip110 level under normoxia in a dose-dependent
manner (Fig. 4A). In agreement with the previous findings (Fig.
3), p53 expression promoted Tip110 degradation under hypoxia.
FIG 1 Tip110 degradation under hypoxia. (A and B) SW480 cells were transfected with Tip110-His, treated with 20M MG132, cultured at 21 or 1% O2 for 24
h, and harvested for Tip110 expression by Western blotting (A). The Tip110 protein level was quantitated using the loading control -actin as a reference (B).
Rel., relative. (C) SW480 cells were transfected with Ub-HA, Tip110-His, or both, treated with 20 M MG132, and cultured at 21 or 1% O2 for 24 h. Cell lysates
were immunoprecipitated (IP) using an anti-His antibody, followed by Western blotting using an anti-HA antibody. -Actin was included as a loading control
for Western blotting. The data are representative of three independent experiments.
FIG 2 Relationship between Tip110, p53, and HIF-1. (A and B) SW480 cells were transfected with increasing amounts of Tip110-His, cultured at 21% O2 for
24 h, and harvested for Tip110, p53, and HIF-1 expression by Western blotting. cDNA3 was used to equalize the total amount of DNA among all transfections
(A). HIF-1 and p53 protein levels were quantitated using -actin as a reference (B). -Actin was included as a loading control for Western blotting.
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To determine whether p53 would transactivate Tip110 transcrip-
tion, Saos-2 cells were transfected with a Tip110 promoter-driven
luciferase reporter plasmid, pGL3.Tip110-Prom-Luc, and in-
creasing amounts of p53 expression plasmids, cultured under nor-
moxia and hypoxia, and harvested for the luciferase reporter gene
activity assay. p53 expression transactivated the Tip110 promoter-
driven luciferase reporter gene in a dose-dependent manner un-
der both normoxia and hypoxia, although the transactivation was
greater under normoxia than that under hypoxia (Fig. 4B). These
results showed that p53 transactivated Tip110 transcription and
increased Tip110 protein levels under normoxia and confirmed
that p53 promoted Tip110 degradation under hypoxia.
Regulation of p53 and HIF-1 stability by Tip110. Next, we
determined whether Tip110 expression would alter p53 and
HIF-1 protein levels under both normoxic and hypoxic condi-
tions. U2OS and Saos-2 were transfected with Tip110-His, cul-
tured under normoxia and hypoxia, and then analyzed for p53
and HIF-1 protein levels. In U2OS, Tip110 expression showed
more increases in p53, p300, and HIF-1 protein levels under
hypoxia (Fig. 5A and B). In Saos-2 cells, Tip110 expression also led
to increased HIF-1 and p300 protein levels under both normoxia
and hypoxia (Fig. 5C and D). In addition, U2OS and Saos-2 were
transfected with Tip110 siRNA or control siRNA, cultured under
normoxia and hypoxia, and then analyzed for p53 and HIF-1
protein levels. Tip110 knockdown led to more decreases of the
p53 and HIF-1 protein levels in U2OS cells under hypoxia (Fig.
6A and B) and lower levels of HIF-1 in Saos-2 cells under nor-
moxia and hypoxia (Fig. 6C and D). To determine whether the
increased p53 protein occurred at the transcriptional level, U2OS
FIG 3 Effects of p53 on Tip110 degradation under hypoxia. (A and B) U2OS cells expressing wild-type p53 (p53/) or Saos-2 cells expressing no p53 (p53/)
were cultured under 21, 1, or 0.1% O2 for 24 h and harvested for Tip110, HIF-1, p300, and p53 expression by Western blotting (A). Levels of Tip110, HIF-1,
p300, and p53 protein expression were quantitated using -actin as a reference (B). (C and D) U2OS cells were transfected with a universal siRNA control
(Si-Ctrl) or p53 siRNA (Si-Tip110), cultured under 21, 1, or 0.1% O2 for 24 h, and harvested for Western blotting (C). Levels of Tip110, HIF-1, p300, and p53
protein expression were quantitated using -actin as a reference (D). The data are representative of three independent experiments.
FIG 4 Effects of p53 expression on Tip110 protein and transcription under hyp-
oxia. (A) Saos-2 cells were transfected with the indicated amounts of p53, cultured
at 21 or 1% O2 for 24 h, and harvested for Tip110 and p53 protein expression by
Western blotting. cDNA3 was used to equalize the total amount of DNA among all
transfections. -Actin was included as a loading control. (B) Saos-2 cells were
transfected with 250 ng pGL3-Tip110 Prom-Luc alone or in combination with 0.5,
1, and 2g p53 for24handculturedunder21or1%O2 for24h.Cellswereharvested
for the luciferase reporter gene assay. cDNA3 was used to equalize the total amount of
DNA among all transfections. pTK-gal was included to normalize the transfection
efficiency variations among all transfections. The data are means
 standard errors
(SE) of triplicate samples and representative of three independent experiments. ***,
strongly significant (P 0.001); NS, not significant.
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cells were transfected with Tip110-His, cultured under normoxia
and hypoxia, and harvested for determination of Tip110 and p53
mRNA levels by qRT-PCR. Consistent with previous findings
(Fig. 1 to 3), hypoxia showed little effects on the Tip110 mRNA level (Fig. 7A). As expected, hypoxia showed little increases in p53
mRNA (39, 40). Tip110 expression showed no effects on the p53
mRNA level under both normoxia and hypoxia (Fig. 7B). To de-
termine whether Tip110 expression also led to increased stability
of HIF-1, we performed the reoxygenation experiment. U2OS
cells were transfected with Tip110-His, cultured under hypoxia
for 24 h, and then transferred to normoxia for different lengths of
time and harvested for Tip110 and HIF-1 expression by Western
blotting. In the absence of Tip110 overexpression, the hypoxia-
induced HIF-1 protein became gradually degraded (41, 42)
(Fig. 8A and B). In contrast, in the presence of Tip110 overexpres-
sion, there was little change in hypoxia-induced HIF-1 protein.
In addition, the p53 protein level was also determined. Consistent
with a previous report (43), reoxygenation led to p53 stabilization.
As shown before (Fig. 1, 3, and 6), Tip110 overexpression also led
to increased p53 stability after reoxygenation. HIF-1 and p53
protein turnover was further determined by treatment of Tip110-
transfected U2OS or its control with deferoxamine mesylate (DFO), a
chemical that has been widely used to mimic hypoxia by blocking
HIF-1protein degradation (44), for 24 h with addition of cyclohex-
imide, an inhibitor of protein synthesis, for various lengths of time,
and then harvested to determine HIF-1 and p53 protein expression
by Western blotting. Consistent with our previous observations,
overexpression of Tip110 increased the half-life of p53 and HIF-1
(Fig. 8C and D). These results together suggest that Tip110 expression
increased p53 and HIF-1 protein stability.
Involvement of p300 in Tip110-p53mutual regulation. p300
is a multifunctional transcription coactivator for p53 and HIF-1;
FIG 5 Effects of Tip110 expression on p53 and HIF-1 under hypoxia. (A to
D) U2OS (A) and Saos-2 (C) cells were transfected with a Tip110-His or
cDNA3 plasmid for 24 h and cultured under 21% or 1% O2 for 24 h. Cells were
harvested and prepared for Tip110, p53, HIF-1, and p300 protein expression
by Western blotting. Levels of Tip110, HIF-1, p300, and p53 protein expres-
sion were quantitated using -actin as a reference (B and D). The data are
representative of three independent experiments.
FIG 6 Effects of Tip110 knockdown on p53 and HIF-1 under hypoxia. (A to D)
U2OS (A) and Saos-2 (C) cells were transfected with a universal siRNA control (Si-
Ctrl) or Tip110 siRNA (Si-Tip110) for 48 h and cultured under 21 or 1% O2 for 24 h.
Levels of Tip110, HIF-1, and p53 protein expression were quantitated using-actin
asareference(BandD).Thedataarerepresentativeofthreeindependentexperiments.
FIG 7 Effects of hypoxia on Tip110 and p53 mRNA levels. U2OS cells were
transfected with a Tip110-His or cDNA3 plasmid for 24 h and cultured under 21
or 1% O2 for 24 h. The cells were harvested for total RNA isolation, and qRT-PCR
was performed to determine the Tip110 mRNA level (A) and p53 mRNA level (B).
-Actin was included in the qRT-PCR to estimate relative Tip110 and p53 mRNA
levels. Tip110 and p53 mRNA levels in cells that were transfected with cDNA3 and
cultured under normoxia were set at 1. The data are means
 SE from triplicate
samples and representative of three independent experiments. **, highly signifi-
cant (P 0.01); ***, strongly significant (P 0.001); NS, not significant.
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its interaction with p53 and HIF-1 regulates a number of cellular
genes (45, 46). The finding that Tip110 expression led to an in-
creased p300 protein level (Fig. 5A to D) prompted us to investi-
gate the roles of p300 in Tip110-p53 reciprocal regulation. We first
determined whether Tip110 would activate p300 expression at the
transcriptional level in the absence of p53 expression. To address
this possibility, Saos-2 cells were transfected with the p300 pro-
moter-driven luciferase reporter gene (47) and increasing
amounts of Tip110-His, cultured under normoxia and hypoxia,
and harvested for the luciferase reporter gene assay. Tip110 ex-
pression transactivated the p300 promoter-driven luciferase re-
porter gene expression in a dose-dependent manner under both
normoxic and hypoxic conditions (Fig. 9A). The residues Gln22
and Ser23 in the N-terminal transactivation domain of p53 are
required for p53 binding to p300/CBP transcriptional coactiva-
tors and critical for its interaction with Mdm2 (33, 45, 48). Thus,
we then took advantage of the p53(22/23) double mutant and
determined its effects on the Tip110 protein level. Saos-2 cells
were transfected with wild-type p53 or the p53(22/23) mutant,
cultured under normoxia and hypoxia, and harvested for Tip110
expression by Western blotting. Consistent with our previous re-
sults (Fig. 4A), overexpression of wild-type p53 led to increased
Tip110 protein under normoxia but decreased Tip110 protein
under hypoxia (Fig. 9B). In comparison, expression of p53(22/23)
FIG 8 Tip110’s effects on HIF-1 protein stability. (A) U2OS cells were transfected with Tip110-His or cDNA3 and cultured under 1% O2 for 24 h. The cells were then
cultured under 21% O2 (also known as reoxygenation) for the indicated lengths of time before being harvested for Tip110, HIF-1, and p53 expression by Western
blotting. (B) Levels of HIF-1 and p53 protein expression were quantitated by using a loading control for Western blotting,-actin, as a reference. (C) U2OS cells were
transfected with a Tip110-His or cDNA3 plasmid and then treated with DFO (250 M) for 24 h. Cycloheximide (CHX) (40 g/ml) was added at the indicated times
before cells were harvested. (D) Levels of HIF-1 and p53 protein expression were quantitated using -actin as a reference.
FIG 9 p300 transactivation by Tip110. (A) Saos-2 cells were transfected with 250 ng pGL3.p300-Prom-Luc reporter alone or in combination with 0.5, 1, and 2
g pTip110 for 24 h and cultured under 21% or 1% O2 for 24 h. Cells were harvested for the luciferase reporter gene assay. cDNA3 was used to equalize the total
amount of DNA among all transfection. The pTK-gal plasmid was included to normalize the transfection efficiency variation among all transfections. The data
represent means
 SE from triplicate samples and are representative of three independent experiments. (B) Saos-2 cells were transfected with either p53 or the
p53(22/23) mutant for 24 h. Cells were cultured under 21% or 1% O2 for 24 h and harvested for Tip110, HIF-1, and p53 expression by Western blotting. Tip110
protein expression was quantitated by using-actin as a reference. The data are representative of three independent experiments. **, highly significant (P 0.01).
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led to less increased Tip110 protein under normoxia but a signif-
icantly greater reduction of Tip110 protein under hypoxia. On the
other hand, p53(22/23) had little effect on HIF-1 protein levels
(38). These results provided evidence to support that p300 is in-
volved in Tip110-p53 mutual regulation.
Tip110 knockdown inhibited cell proliferation. Altered reg-
ulation of p53 and HIF-1 protein levels under normoxia and
hypoxia likely leads to changes in cell proliferation (34). To assess
the outcomes of Tip110 –p53–HIF-1 interaction, U2OS and
Saos-2 were transfected with Tip110 siRNA, cultured under nor-
moxia and hypoxia, and harvested for cell proliferation by MTT
assay and for cell cycle analysis by flow cytometry. Compared to
the control siRNA, Tip110 knockdown inhibited U2OS prolifer-
ation but showed no effects on Saos-2 under both normoxia and
hypoxia (Fig. 10A). Meanwhile, compared with the control
siRNA, Tip110 knockdown led to 2-fold increases in the sub-G0
(apoptotic) fraction and 2-fold decreases in the G2/M fraction in
U2OS cells, while it showed no effects in Saos-2 cells (Fig. 10B).
Nevertheless, Tip110 overexpression showed no effects on cell
proliferation or apoptosis in both U2OS and Saos-2 cells (data not
shown), likely due to a relatively higher level of constitutive
Tip110 expression in those cells. These results indicate that Tip110
plays an important role in regulation of cell proliferation and sur-
vival in the context of p53 protein.
Decreased Tip110 expression in the core region of bone can-
cer tissues. To further investigate the relationship among Tip110,
p53, and HIF-1 expression, we used a bone metastasis mouse
model derived from inoculation of the human bone metastatic
cancer cell line 1205L, a melanoma line expressing wild-type p53,
into athymic nude mice (31, 49). Immunofluorescence staining
was performed for Tip110, HIF-1, and p53 expression on the
longitudinal section of the bone metastases from osteolytic bone
tumor (humerus region). Tip110 was detected throughout the
normal bone tissues (Fig. 11A), but there was little Tip110 expres-
sion detected in the central hypoxic region of the tumor (labeled
“T” in Fig. 11B) compared to that in the peripheral region (Fig.
11B, Tip110 panels, arrowheads). In addition, significantly less
HIF-1 and p53 were also detected in the same regions where less
Tip110 was detected (Fig. 11B, p53 and HIF-1 panels). To vali-
date these findings, we directly cultured 1205Lu cells under severe
hypoxia (0.1% O2) for up to 72 h and then harvested them for
protein expression analysis. Endogenous Tip110, p53, and
HIF-1 protein levels were significantly downregulated under se-
vere hypoxia in a similar fashion (Fig. 11C and D). Interestingly,
p300 protein expression was also downregulated in those cells
under the same conditions. These results support the notion that
there is a complicate intertwined regulatory network among
Tip110, p53, HIF-, and p300 under hypoxia.
DISCUSSION
The Tip110 protein level is regulated during hematopoietic stem
cell proliferation and differentiation (19), which are known to
reside in bone marrow hypoxic microenvironments (partial O2
pressure [pO2] of between 1 and 7%) (50). Furthermore, Tip110
interacted with oncogenic proteins that play an important role
during hypoxia (11, 19). Thus, these observations prompted us to
investigate the regulatory mechanism of Tip110 under limited-
oxygen conditions. In this study, we showed that Tip110 protein
levels were downregulated in human cancer cell lines cultured
under hypoxic conditions (Fig. 1 to 4) (other data not shown).
Downregulation of Tip110 protein was mainly achieved by the
ubiquitin proteasome system (UPS)-mediated protein degrada-
tion pathway (Fig. 1 and 7). In addition, Tip110 regulated the p53
and HIF-1 proteins’ stability, whereas p53 expression was re-
FIG10 Effects of Tip110 expression on cell proliferation and cell cycle. U2OS and Saos-2 cells were transfected with a universal control siRNA (Si-Ctrl) or Tip110
siRNA (si-Tip110) for 48 h and then cultured under 21% or 1% O2 for 24 h. The cells were harvested for cell proliferation by MTT assay (A) or for cell cycle
analysis by flow cytometry (B). O.D, optical density; Apop., apoptosis. The data are means 
 SE from triplicate samples (A) and are representative of three
independent experiments (A and B). *, statistically significant (P 0.05); **, highly significant (P 0.01).
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sponsible for Tip110 downregulation under hypoxia (Fig. 1 to 7).
Furthermore, we showed that p300 was involved in Tip110-p53
reciprocal regulation (Fig. 9 and 11). Finally, we showed that
Tip110 expression altered cell proliferation and survival in the
context of p53 protein (Fig. 10).
We have previously reported that Tip110 and c-Myc recipro-
cally regulate each other’s gene expression, suggesting a positive-
feedback-loop regulation between Tip110 and c-Myc (19, 20).
Similar to Tip110, the expression of c-Myc protein levels in cancer
cells is significantly downregulated under hypoxia and glucose-
deprived conditions through UPS-mediated protein degradation
(51). Suppression of c-Myc decreases necrotic cell death induced
by oxygen and glucose deprivation, which might be a strategy for
cancer cells to survive under conditions of limited energy re-
sources (51). In addition, we have also shown that YB-1, an onco-
genic transcription factor, and Tip110 form a complex and recip-
rocally regulate each other’s function (11). Hypoxia has been
shown to induce phosphorylation of YB-1, which could induce
the expression of proangiogenic factors that are important for
tumor progression (29). Thus, these observations supported our
findings that Tip110 plays an important role in host response to
limited-oxygen conditions.
Upregulation of p53 by Tip110 expression (Fig. 5) is more
likely through increased p53 protein stability, as there was no sig-
nificant change in the p53 mRNA in the presence or absence of
Tip110 under hypoxic condition (Fig. 7 and 8). On the other
hand, p53 promoted Tip110 degradation under hypoxia and
transactivated Tip110 transcription under normoxia (Fig. 4),
which suggests that Tip110 and p53 regulate each other mainly
through protein stabilization, whereas regulation of Tip110 tran-
scription by p53 could be an additional mechanism that may reg-
ulate Tip110 protein homeostasis. Studies have shown that the
increase in the p53 protein level during hypoxia is due to stabili-
zation and is dependent on the presence of HIF-1 (52, 53). How-
ever, HIF-1 upregulation is not sufficient for p53 induction (54).
Hypoxia-induced p53 fails to transactivate its target genes (55).
Wild-type p53 has been shown to function as a molecular chaper-
one and to rescue mutant p53 in hypoxic tumors and subse-
quently cause tumor regression (56). There are multiple contra-
dictory reports on reciprocal interaction of p53 with hypoxic
signaling (39, 54, 57–60). These inconsistencies may likely be due
to the types of cell lines used, the severity and the duration of
hypoxia, and unknown cellular factors that under oxygen defi-
ciency influence very differently the p53 protein level (34). The
Tip110-p53 reciprocal regulation could contribute to the magni-
tude of Tip110 protein reduction in different cancer cell lines un-
der similar hypoxic conditions (Fig. 1 to 5).
Tip110 overexpression resulted in the stabilization of HIF- in
U2OS cells under hypoxia (Fig. 5 and 8). However, in Saos-2 cells,
the level of HIF-1 was highly increased when Tip110 was over-
expressed under both normoxic and hypoxic conditions (Fig. 5C
and D). p53 knockout mice have a higher HIF-1 protein level
than wild-type mice following chronic hypoxia exposure (61).
HIF-1 is overexpressed in metastatic osteosarcoma tumors (62)
and plays important roles in bone repair (63). Amplification of
HIF-1-dependent responses to hypoxia via loss of p53 function
contributes to the angiogenic switch during tumorigenesis (38).
Furthermore, HIF-1 expression correlates with increasing tu-
mor grade, invasion, and metastasis (64). Overexpression of c-
Myc protein, which forms a reciprocal regulatory loop with
Tip110 (19, 20), significantly stabilizes HIF-1 under normoxic
conditions, enhances HIF-1 accumulation under hypoxic con-
ditions, and is important for cancer development (65). Thus, there
is a high probability that the level of Tip110 protein in response to
limited-oxygen conditions contributes to the stability of p53
and/or HIF-1 during tumorigenesis.
FIG 11 Tip110, p53, and HIF- expression in mouse bone metastases. (A and B) Mouse osteolytic bone metastasis tissues were obtained by inoculating cells of
the human bone metastatic cancer melanoma cell line, 1205Lu (which contains wild-type p53), into the bones of athymic nude mice. Longitudinal sections of
control (A) or metastasis (B) bone were prepared and immunostained for Tip110, p53, and HIF-1 expression. DAPI was used to visualize the nuclear DNA. T,
tumor core region; arrowheads, peripheral tissues. (C and D) 1205Lu cells were cultured under severe hypoxia (0.1% O2) for the indicated lengths of time and
then harvested for expression of the Tip110, p53, HIF-1, and p300 proteins by Western blotting (C). Levels of protein expression were quantitated by using
-actin as a reference (D).
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We have shown that Tip110 upregulated p300 in Saos-2 under
both normoxic and hypoxic conditions (Fig. 5C and D and Fig.
9A), and the expression of the p53(22/23) mutant, which is defi-
cient in p300 binding, led to further reduction of Tip110 under
hypoxia compared to the p53 wild type (Fig. 9B). p300 acts as
transcriptional coactivator for several nuclear proteins involved in
proliferation, cell cycle regulation, apoptosis, differentiation, and
the DNA damage response (66). Among these factors are known
oncoproteins, such as c-Jun and c-Fos, and tumor suppressor pro-
teins, such as E2F, pRB, p53, and Smads (66). In addition, several
studies have proposed a competition between p53 and HIF-1 for
the limited amount of the shared transcriptional coactivator p300
(67, 68). Thus, depending on the relative amount of expression of
either of those two factors in the context of Tip110 expression, this
competition would explain how both p53 transcriptional activity
and HIF-1 transcriptional activity are affected.
Although overexpression of Tip110 in either U2OS or Saos-2
cells has no effect on the cells’ proliferation or apoptosis (data not
shown), knockdown of Tip110 resulted in inhibition of the cells’
proliferation and an increase in the number of apoptotic cells in
U2OS only, yet no such effect was observed in Saos-2 cells (Fig.
10A and B). Interestingly, knockdown of Tip110 was more pro-
nounced in U2OS cells than in Saos-2 cells cultured under hypoxia
and under the same transfection conditions; however, the HIF-1
protein level was dramatically reduced in both cell types (Fig. 6A
to D). Knockdown of HIF-1 enhances expression of HIF-2, and
vice versa, which results in increased cell viability and inhibits
apoptosis (69). Thus, inhibition of cell proliferation by knock-
down of Tip110 could be a consequence of the effect of Tip110 on
the level of hypoxia-inducible factors in the presence of p53 under
hypoxia, which merits further investigation.
It is known that tumor tissues experiencing hypoxia will be
exposed to oxygen levels that vary in amplitude and duration
(acute or chronic hypoxia) (70). Hypoxia and transforming
growth factor  (TGF-) signaling drive tumor bone metastases
in a bone metastasis mouse model (71). Using the same mouse
model, we found little Tip110 protein expression in the central
hypoxic region of the tumor and significantly reduced levels of
HIF-1 and p53 in the same regions (Fig. 11A and B). c-Myc
protein expression has been detected in the tumor area proximal
to the blood vessels (moderate hypoxia), but no c-Myc was de-
tected in the tumor area distant from blood vessels (severe hyp-
oxia or anoxia) (51). Similarly to c-Myc, the Tip110 expression
level was O2 concentration dependent (Fig. 3), and knockdown of
Tip110 resulted in reduction of p53 and HIF-1 under hypoxic
conditions (Fig. 6A and B). Although the Tip110 protein level is
highly elevated in a number of malignant tumor cell lines and
cancerous tissues (16–25), it is also possible that the Tip110 ex-
pression level is affected by the tumor microenvironment, such as
under low oxygen tension. Taken together, these results indicate
that the control of Tip110 protein level may have important func-
tional consequences on the cross talk with key signaling pathways
controlling cell survival, which is likely to have an impact on p53
and HIF targeting strategies for hypoxia-associated diseases.
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